insights_auto
Why is BOT up 11.11%?
Dive Deeperchevron_right
BOT:ASX
Botanix Pharmaceuticals Ltd
A$0.010
arrow_upward
+11.11%(+0.0010) 1D
Nov 3, 4:11:05 PM GMT+11 · AUD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BOT...
Open
A$0.01
High
A$0.01
Low
A$0.01
Mkt. cap
27.63M
Avg. vol.
9.67M
Volume
6.65M
52-wk high
A$0.15
52-wk low
A$0.01
EPS
-A$0.03
Shares outstanding
2.76B
No. of employees
11
Open
A$0.01
High
A$0.01
Low
A$0.01
Mkt. cap
27.63M
Avg. vol.
9.67M
Volume
6.65M
52-wk high
A$0.15
52-wk low
A$0.01
EPS
-A$0.03
Shares outstanding
2.76B
No. of employees
11
News stories
From web sources and news partners
FinancialContent
·
1 hour ago
Chegg’s (NYSE:CHGG) Q3 2026: beats on revenue but quarterly revenue guidance slightly misses expectations
PR Newswire Canada
·
23 minutes ago
NYSE-Affiliated Venue for Tokenization Adds Transfer Agents: NYSE Content Update
Barchart.com
·
1 hour ago
Upstart (NASDAQ:UPST) posts better-than-expected sales in Q3 2026, stock soars
Seeking Alpha
·
32 minutes ago
It's Time To Go All-In On Stocks (SP500)
Profile
Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol. The company's lead product is Sofdra, which treats axillary hyperhidrosis. The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex, for direct skin delivery of active pharmaceuticals which is utilised in all of their programs. Wikipedia
About Botanix Pharmaceuticals Ltd